Multifunctional injectable hydrogel for treating cerebral arterial thrombosis as well as preparation method and application of multifunctional injectable hydrogel

By developing injectable NO-release gelatin and MIF inhibitor nanoparticle cross-linked hydrogels, the neuroprotection and blood-brain barrier problems in the treatment of ischemic stroke were solved, and the recovery of nerve function and angiogenesis were achieved, with significant improvements in neurologic function and angiogenesis. Patient prognosis and quality of life.

CN119055583AActive Publication Date: 2024-12-03SICHUAN UNIV
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411228796.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-03
Publication Date
2024-12-03
Estimated Expiration
2044-09-03

AI Technical Summary

Technical Problem

Patients with ischemic stroke lack effective neuroprotective drugs. The existing treatment plans have problems with narrow time window, poor drug stability and blood-brain barrier blockage, which leads to limited treatment effects and is difficult to achieve neurological recovery.

Method used

Develop a multifunctional injectable hydrogel, including grafted gelatin that sustainably releases NO and nanoparticles loaded with MIF inhibitors, cross-links with drug-loaded nanoparticles through oxidized dextran to form a cerebral ischemia environment Hydrogels that play nerve damage repair, anti-inflammatory and pro-angiogenesis.

Benefits of technology

This hydrogel can achieve nerve damage repair, anti-inflammatory, anti-blood-brain barrier destruction and promote angiogenesis in a cerebral ischemic environment, significantly improve the prognosis of ischemic stroke and improve the quality of life of patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055583A_ABST
    Figure CN119055583A_ABST
Patent Text Reader

Abstract

The invention discloses multifunctional injectable hydrogel for treating cerebral arterial thrombosis as well as a preparation method and application of the multifunctional injectable hydrogel, and belongs to the technical field of biological medicines. The multifunctional injectable hydrogel comprises a colloid capable of continuously releasing NO and drug-loaded nanoparticles crosslinked with the colloid, wherein the drug-loaded nanoparticles are loaded with an MIF inhibitor. The prepared continuous slow-release NO multifunctional hydrogel loaded with the PF127B-coated ISO-1 nanoparticles can respond to a microenvironment, can play the functions of nerve injury repair, inflammation resistance, blood brain barrier damage resistance and angiogenesis promotion in a cerebral ischemia microenvironment, and finally realizes neurological function recovery after ischemic stroke.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of biomedicine, and in particular relates to a multifunctional injectable hydrogel for treating ischemic stroke, and a preparation method and application thereof. Background Art

[0002] Stroke is a global disease that seriously threatens human life and health, and is also one of the main causes of death in the global population. Among them, ischemic stroke (cerebral infarction) is the most common type of stroke, accounting for about 80%. In conventional treatment plans, the time window for acute mechanical thrombectomy and intravenous thrombolysis is narrow, and most patients with cerebral infarction fail to benefit, and may also be accompanied by related complications. In addition, because the process of ischemic injury and chronic recovery is very complicated, the treatment mechanism has the characteristics of multiple targets and multiple pathways.

[0003] At present, there are few clear and effective neuroprotective drugs for the recovery period after cerebral ischemia in clinical practice, and the effects of approved neuroprotective agents are relatively limited. Therefore, the current mortality and disability rates of cerebral infarction are extremely high, which seriously endangers human health, brings huge burdens to families and society, and is one of the important reasons for poverty due to illness. After cerebral infarction, the brain causes cellular metabolic disorders due to ischemia and hypoxia, which causes a series of pathological and physiological processes. For example, excitotoxicity, oxidative stress, and mitochondrial dysfunction can induce a variety of cellular cascade reactions, ultimately leading to neuronal apoptosis, necrosis, and autophagy. The pathophysiological mechanisms after cerebral infarction are complex and have many targets. This is one of the reasons why the current treatment of a single therapeutic target after cerebral infarction is not effective.

[0004] In addition, another obstacle is the protective effect of the blood-brain barrier. As a biological barrier that protects the brain from toxins and infections, the blood-brain barrier also prevents most therapeutic drugs from effectively entering the brain, and most therapeutic drugs have problems such as short circulation time, poor stability, and self-toxicity. Therefore, it is a difficult problem that needs to be solved urgently in the clinic to find a comprehensive treatment method that can continuously repair nerve damage, reasonably control neuroinflammation, and promote angiogenesis, and use new technical means to enable these key molecules to play a role in the core part of ischemic brain injury, so as to improve the prognosis of ischemic brain injury and improve the quality of life of patients with cerebral infarction. Summary of the invention

[0005] In view of the above-mentioned deficiencies in the prior art, the present invention provides a multifunctional injectable hydrogel for treating ischemic stroke, and a preparation method and use thereof, which can play the functions of nerve damage repair, anti-inflammation, anti-blood-brain barrier destruction and promoting angiogenesis in the cerebral ischemic microenvironment, and ultimately achieve neurological function recovery after ischemic stroke.

[0006] To achieve the above purpose, the technical solution adopted by the present invention to solve the technical problem is:

[0007] A multifunctional injectable hydrogel for treating ischemic stroke comprises a colloid capable of sustainably releasing NO and drug-loaded nanoparticles cross-linked therewith; the drug-loaded nanoparticles are loaded with a MIF inhibitor.

[0008] Furthermore, the colloid that can release NO continuously is gelatin grafted with an NO donor, which is cross-linked with drug-loaded nanoparticles via oxidized dextran.

[0009] Furthermore, the preparation method of gelatin grafted with NO donor is as follows:

[0010] (1) placing bromoacetic acid and silver nitrate in anhydrous acetonitrile, stirring at 70-90° C. for 15-18 hours, filtering, concentrating the filtrate under vacuum, then adding dichloromethane, incubating at room temperature for 2-5 hours, and filtering again to remove dichloromethane to obtain 2-(nitrooxy)acetic acid;

[0011] (2) Activate the carboxyl group of 2-(nitrooxy)acetic acid in a buffer solution, then add gelatin and stir the reaction for 42 to 50 hours to obtain gelatin G grafted with NO donor. NO .

[0012] Furthermore, the weight ratio of bromoacetic acid to silver nitrate is 1:1.5-2.

[0013] Furthermore, NHS and EDC were used to activate the carboxyl group of 2-(nitrooxy)acetic acid.

[0014] Furthermore, the buffer is 2-morpholineethanesulfonic acid, and its pH value is 6.

[0015] Furthermore, the preparation method of drug-loaded nanoparticles is as follows:

[0016] (1) Add 4-carboxyphenylboronic acid, EDC and catalyst to PF127 solution, react at 40-50° C. for 20-30 h in a protective gas atmosphere, filter and concentrate, precipitate with precooled ether, and then dialyze and freeze-dry for later use;

[0017] (2) The product obtained in step (1) and the MIF inhibitor are dissolved and ultrasonically homogenized, and the organic solvent is removed by rotary vacuum evaporation to obtain a uniform thin film, and then water at 40 to 50° C. is added and ultrasonically hydrated at 40 to 50° C. After the thin film is peeled off, it is filtered with a filter membrane to obtain the drug-loaded nanoparticles.

[0018] Furthermore, the mass ratio of PF127, 4-carboxyphenylboric acid, EDC and catalyst is 10-20:0.5-2:1-2:0.1-0.8.

[0019] Furthermore, the catalyst is DMAP.

[0020] Furthermore, the MIF inhibitor is ISO-1.

[0021] The preparation method of the multifunctional injectable hydrogel comprises: NO , oxidized dextran and drug-loaded nanoparticles were mixed and stirred evenly, and then G NO The drug-loaded nanoparticles can be cross-linked by oxidized dextran.

[0022] Furthermore, G NO The mass ratio of oxidized dextran is 1:1.

[0023] Further, the preparation method of oxidized dextran is as follows:

[0024] Dextran and sodium periodate were dissolved in deionized water (DW) and stirred at 37°C for 4 h; then, ethylene glycol was added and stirred for 2 h to mix evenly, and finally dialyzed with DW and freeze-dried to obtain the product.

[0025] The multifunctional injectable hydrogel is used in preparing drugs for repairing nerve damage, promoting angiogenesis, resisting blood-brain barrier damage or treating ischemic stroke.

[0026] Beneficial effects of the present invention:

[0027] The multifunctional hydrogel containing PF127B@ISO-1 nanoparticles prepared by the present invention can respond to the microenvironment and play the functions of nerve damage repair, anti-inflammation, anti-blood-brain barrier destruction and promoting angiogenesis in the cerebral ischemic microenvironment, ultimately achieving neurological function recovery after ischemic stroke. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 To test the performance of the multifunctional injectable hydrogel prepared according to the present invention;

[0029] Figure 2 The expression of inflammation, angiogenesis and neuroprotection related proteins in the brain of experimental mice after drug administration;

[0030] Figure 3 The changes of neurological function and behavior of experimental mice after drug administration over time;

[0031] Figure 4 It is the motor activity level of the experimental mice after medication. DETAILED DESCRIPTION

[0032] The specific implementation modes of the present invention are described below so that those skilled in the art can understand the present invention. However, it should be clear that the present invention is not limited to the scope of the specific implementation modes. For those of ordinary skill in the art, as long as various changes are within the spirit and scope of the present invention as defined and determined by the attached claims, these changes are obvious, and all inventions and creations utilizing the concept of the present invention are protected.

[0033] Example 1 Preparation of multifunctional injectable hydrogel

[0034] 1. Preparation of NO-grafted gelatin (G NO )

[0035] Bromoacetic acid (2.00 g, 14.3 mmol) and silver nitrate (3.70 g, 21.8 mmol) were stirred in anhydrous acetonitrile (80 mL) at 70 ° C for 18 h. After filtration, the product was concentrated in vacuo and dichloromethane (100 mL) was added. The mixture was incubated at room temperature for 2 h and filtered again, and then dichloromethane was removed to obtain 2-(nitrooxy)acetic acid as a yellow oil. 2-(Nitrooxy)acetic acid (3.5 mL), N-hydroxysuccinimide (NHS) (6.3 g), 1-ethyl-(3-dimethylaminopropyl)carbodiimide (EDC) (10.5 g) were dissolved in 100 mL 2-morpholineethanesulfonic acid (MES) buffer (pH 6.0) to activate the carboxyl group. After 2 h, gelatin (5.5 g) was added and stirred for 48 h, then dialyzed with deionized water and freeze-dried to obtain G NO .

[0036] 2. Synthesis of PF127-BA

[0037] (1) 20 g of PF127 was dissolved in dichloromethane, and then 1.5 g of 4-carboxyphenylboronic acid, 1.92 g of EDC, and 611 mg of 4-dimethylaminopyridine (DMAP) were added respectively. The mixture was reacted at 40 °C for 24 h under nitrogen protection. The reactant was filtered, concentrated, and added dropwise to precooled ether for precipitation, and then dialyzed and freeze-dried in a methanol / water solution.

[0038] (2) Weigh 100 mg of PF127B and 10 mg of ISO-1 and dissolve them in 5 mL of tetrahydrofuran respectively. Ultrasonicate in a water bath for 10 minutes to fully dissolve the mixture. Remove the organic solvent by rotary evaporation at 40°C, leaving a uniform film on the bottle. Add 20 mL of a preheated 40°C aqueous solution into the rotary evaporator and ultrasonicate in a 40°C water bath until the film on the bottle wall is peeled off. Filter with a 0.22 μm filter membrane and store at 4°C to obtain PF127-BA.

[0039] 3. Preparation of oxidized dextran

[0040] 10.0 g of dextran and 8.0 g of sodium periodate were dissolved in deionized water (DW) and stirred at 37°C for 4 h. Then, 1.2 mL of ethylene glycol was added to the above solution and stirred for 2 h to mix well. Finally, the solution was dialyzed with deionized water (DW) for 48 h and lyophilized to obtain oxidized dextran (OD).

[0041] 4. Preparation of hydrogel

[0042] The synthesized NO-grafted gelatin, oxidized dextran and PF127 nanoparticles encapsulating ISO-1 are reacted, and the NO-grafted gelatin and the ISO-1-encapsulating PF127 nanoparticles can be cross-linked through the oxidized dextran to prepare the hydrogel.

[0043] Example 2

[0044] 1. The performance of the hydrogel prepared in Example 1 was tested, and the results are shown in Figure 1 . Figure 1 In the figure, (A) is the detection of typical peaks of each component by hydrogen nuclear magnetic resonance spectrum; (B) is the injectability and gelation properties of the synthesized hydrogel; (C) is the rheological properties detection of three hydrogels, among which: Gel1 is Gel-NO; Gel2 is Gel-NO-PF127BA; Gel3 is Gel-NO-PF127B@ISO-1.

[0045] like Figure 1 As shown, the present invention has successfully grafted NO donor onto gelatin, and oxidized dextran (OD) and PF127-BA have been successfully synthesized. Typical peaks can be seen in the H NMR spectrum (* marks the typical peaks of each substance, Figure 1 A); at the same time, the hydrogel synthesized by the method of the present invention can have a fixed shape and has injectability ( Figure 1 B).

[0046] The mechanical properties of the hydrogels were measured by oscillatory shear rheology. The results showed that the storage modulus (G') significantly exceeded the loss modulus (G") and was similar to the modulus of brain tissue. The mechanical properties of the hydrogels matched those of brain tissue. Moreover, when the strain increased, the storage modulus was lower than the loss modulus, indicating that all types of hydrogels prepared by the present invention were injectable ( Figure 1 C).

[0047] 2. Compared with the modeling group (PT group), the photochemically induced ischemic cerebral infarction mouse model was divided into the Gel-NO hydrogel injection group (PT+Gel-NO), the Gel-NO+empty PF127BA nanoparticle hydrogel injection group (PT+Gel-NO-PF127BA), and the Gel-NO+PF127B@MIF inhibitor nanoparticle hydrogel injection group (PT+Gel-NO-PF127B@ISO-1). The expression of inflammation, angiogenesis and neuroprotection-related proteins in the model mice after treatment was evaluated. The results are shown in Figure 2 , Figure 2 The brain tissues of mice in the above groups were immunofluorescently stained and it was found that compared with the sham operation group, TUNEL ( Figure 2 A) 4-HNE ( Figure 2 B) MIF Figure 2 C) and MMP-9 ( Figure 2 D)CD31( Figure 2 E) and α-SMA ( Figure 2 F) The expression of brain tissue in the treatment group was increased.

[0048] 2. Comparison of the modeling group (PT group), the photochemically induced ischemic cerebral infarction mouse model was divided into the Gel-NO hydrogel injection group (PT+Gel-NO), the Gel-NO+empty PF127BA nanoparticle hydrogel injection group (PT+Gel-NO-PF127BA), and the Gel-NO+PF127B@MIF inhibitor nanoparticle hydrogel injection group (PT+Gel-NO-PF127B@ISO-1). The dosage was 10 μL. The treatment of the model mice was evaluated 21 days after medication. The results are shown in Figure 3 , Figure 3 (A) is the neurological function score (mNSS); (B) is the duration of each group of mice on the rotating rod in the rotating rod test; (C) is the distance the mice moved in the open field test; (D) is the speed of the mice moving in the open field test.

[0049] like Figure 3 As shown in Figure 2, after treatment, the neurological function scores (mNSS) of mice with ischemic cerebral infarction decreased ( Figure 3 A) Prolonged time on the rotarod in the rotarod test ( Figure 3 B) Increased distance traveled in the open field test ( Figure 3 C) Speed ​​becomes faster ( Figure 3 D), indicating that the autonomous motor function has recovered well. And the effect is better as the treatment time is prolonged.

[0050] In addition, in the open field test, compared with the modeling group, the motor activity of the treatment group increased significantly, especially the Gel-NO-PF127B@ISO-1 group. As the treatment time prolonged, the motor activity and curiosity about the environment increased ( Figure 4 ).

[0051] According to the above test results, the multifunctional injectable hydrogel prepared by the present invention can be used to treat ischemic cerebral infarction, indicating that it has good clinical significance and application value for the treatment of cerebral infarction.

[0052] Finally, it should be noted that the above specific implementation methods are only used to illustrate the technical solution of the present invention rather than to limit it. Although the present invention has been described in detail with reference to examples, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the spirit and scope of the technical solution of the present invention, which should be included in the scope of the claims of the present invention.

Claims

1. A multifunctional injectable hydrogel for treating ischemic stroke, characterized in that: The invention comprises a colloid capable of continuously releasing NO and drug-loaded nanoparticles cross-linked with the colloid; the drug-loaded nanoparticles are loaded with a MIF inhibitor.

2. The multifunctional injectable hydrogel according to claim 1, characterized in that: The colloid that can release NO continuously is gelatin grafted with NO donor, which is cross-linked with drug-loaded nanoparticles by oxidized dextran.

3. The multifunctional injectable hydrogel according to claim 2, characterized in that: The preparation method of the gelatin grafted with NO donor is as follows: (1) placing bromoacetic acid and silver nitrate in anhydrous acetonitrile, stirring at 70-90° C. for 15-18 hours, filtering, concentrating the filtrate under vacuum, then adding dichloromethane, incubating at room temperature for 2-5 hours, and filtering again to remove dichloromethane to obtain 2-(nitrooxy)acetic acid; (2) Activate the carboxyl group of 2-(nitrooxy)acetic acid in a buffer solution, then add gelatin and stir the reaction for 42 to 50 hours to obtain gelatin G grafted with NO donor. NO .

4. The multifunctional injectable hydrogel according to claim 3, characterized in that: The weight ratio of the bromoacetic acid to silver nitrate is 1:1.5-2.

5. The multifunctional injectable hydrogel according to claim 3, characterized in that: The carboxyl group of 2-(Nitrooxy)acetic acid was activated using NHS and EDC.

6. The multifunctional injectable hydrogel according to claim 1, characterized in that: The preparation method of the drug-loaded nanoparticles is as follows: (1) Add 4-carboxyphenylboronic acid, EDC and catalyst to PF127 solution, react at 40-50° C. for 20-30 h in a protective gas atmosphere, filter and concentrate, precipitate with precooled ether, and then dialyze and freeze-dry for later use; (2) The product obtained in step (1) and the MIF inhibitor are dissolved and ultrasonically homogenized, and the organic solvent is removed by rotary vacuum evaporation to obtain a uniform thin film, and then water at 40 to 50° C. is added and ultrasonically hydrated at 40 to 50° C. After the thin film is peeled off, it is filtered with a filter membrane to obtain the drug-loaded nanoparticles.

7. The multifunctional injectable hydrogel according to claim 6, characterized in that: The mass ratio of the PF127, 4-carboxyphenylboric acid, EDC and catalyst is 10-20:0.5-2:1-2:0.1-0.

8.

8. The multifunctional injectable hydrogel according to claim 1 or 6, characterized in that: The MIF inhibitor is ISO-1.

9. A method for preparing the multifunctional injectable hydrogel according to any one of claims 1 to 8, characterized in that: G NO , oxidized dextran and drug-loaded nanoparticles were mixed and stirred evenly, and then G NO The drug-loaded nanoparticles can be cross-linked by oxidized dextran.

10. Use of the multifunctional injectable hydrogel according to any one of claims 1 to 8 in the preparation of drugs for repairing nerve damage, promoting angiogenesis, resisting blood-brain barrier damage or treating ischemic stroke.

Citation Information

Patent Citations

  • Injectable hydrogel with anti-inflammatory and repair-promoting functions, preparation method of injectable hydrogel and application of injectable hydrogel in heart repair

    CN114585396A

  • Preparation method of fully degradable injectable hydrogel capable of continuously and slowly releasing active molecules

    CN114939189A

  • Double-cross-linked network structure hydrogel, preparation method and application thereof, and repair material

    CN117959494A

  • Method for preparing copper-mediated in situ crosslinkable hydrogel for sustained release of nitric oxide

    WO2023149692A1